Kecheng Huang1, Xiong Li1, Ru Yang2, Jian Shen3, Zhilan Chen4, Xiaomin Qin5, Shaoshuai Wang1, Yao Jia1, Fangxu Tang1, Hang Zhou6, Haiying Sun1, Jin Zhou1, Lili Guo1, Lin Wang1, Long Qiao1, Jiaqiang Xiong1, Congyi Wang7, Ding Ma1, Shuang Li1, Ting Hu1, Shixuan Wang1. 1. Department of Gynecology and Obstetrics, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology PR China. 2. Henan Cancer Hospital PR China. 3. Department of Obstetrics and Gynecology, Wuhan Central Hospital Wuhan, Hubei, PR China. 4. Department of Obstetrics and Gynecology, Wuhan General Hospital of Guangzhou Military Command Wuhan, Hubei, PR China. 5. Department of Obstetrics and Gynecology, Xiangfan Central Hospital, Tongji Medical College, Huazhong University of Science and Technology Xiangfan, Hubei, PR China. 6. Department of Obstetrics and Gynecology, Nanjing Drum Tower Hospital, The Affiliated Hospital of Nanjing University Medical School Nanjing, Jiangsu, PR China. 7. The Center for Biomedical Research, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology Wuhan, Hubei, PR China.
Abstract
OBJECTIVE: This study was designed to evaluate the response, toxicity and survival of taxanes plus platinum (TP) and CPT-11plus platinum (CP) as neoadjuvant chemotherapies with previously untreated cervical cancer, and to identify prognostic risk factors in these patients. METHODS: A cohort study was performed to evaluate the result of TP and CP regimes in the treatment of cervical cancer patients. RESULTS: The study included 567 patients with locally advanced cervical cancer (LACC) staged as FIGO IB-IIB in our clinical departments. Clinical response was found in 76.1% and 78% of patients in the TP and CP arms, respectively, and no treatment-related deaths were reported. During the follow-up period, disease-free survival (DFS) and overall survival (OS) for the TP and CP arms were not different (P = 0.384 for DFS, P = 0.800 for OS). The CP regime showed higher survival rate for endophytic growth style (P = 0.013 for DFS, P = 0.027 for OS). The CP regime also showed higher DFS and OS for G2 tumor (P = 0.027 for DFS, P = 0.032 for OS). In multivariate cox's proportional hazards regression model, the average death rates were much greater in the non-responder group (HR, 2.68), in the older (> 44 years) group (HR, 2.51), and in the FIGO stage II b patients (HR, 2.84). CONCLUSIONS: The CP regime showed higher survival rate for endophytic growth style or G2 tumor. Clinical response, age and FIGO stage were independent prognostic risk factors in this study for both DFS and OS.
OBJECTIVE: This study was designed to evaluate the response, toxicity and survival of taxanes plus platinum (TP) and CPT-11plusplatinum (CP) as neoadjuvant chemotherapies with previously untreated cervical cancer, and to identify prognostic risk factors in these patients. METHODS: A cohort study was performed to evaluate the result of TP and CP regimes in the treatment of cervical cancerpatients. RESULTS: The study included 567 patients with locally advanced cervical cancer (LACC) staged as FIGO IB-IIB in our clinical departments. Clinical response was found in 76.1% and 78% of patients in the TP and CP arms, respectively, and no treatment-related deaths were reported. During the follow-up period, disease-free survival (DFS) and overall survival (OS) for the TP and CP arms were not different (P = 0.384 for DFS, P = 0.800 for OS). The CP regime showed higher survival rate for endophytic growth style (P = 0.013 for DFS, P = 0.027 for OS). The CP regime also showed higher DFS and OS for G2 tumor (P = 0.027 for DFS, P = 0.032 for OS). In multivariate cox's proportional hazards regression model, the average death rates were much greater in the non-responder group (HR, 2.68), in the older (> 44 years) group (HR, 2.51), and in the FIGO stage II b patients (HR, 2.84). CONCLUSIONS: The CP regime showed higher survival rate for endophytic growth style or G2 tumor. Clinical response, age and FIGO stage were independent prognostic risk factors in this study for both DFS and OS.
Authors: Harry J Long; Brian N Bundy; Edward C Grendys; Jo Ann Benda; D Scott McMeekin; Joel Sorosky; David S Miller; Lynne A Eaton; James V Fiorica Journal: J Clin Oncol Date: 2005-05-23 Impact factor: 44.544
Authors: G Di Vagno; G Cormio; S Pignata; G Scambia; M G Di Stefano; R Tambaro; P Trerotoli; G Serio; G Garganese; L Selvaggi Journal: Int J Gynecol Cancer Date: 2003 May-Jun Impact factor: 3.437